224 related articles for article (PubMed ID: 31609457)
1. Homogentisic acid is not only eliminated by glomerular filtration and tubular secretion but also produced in the kidney in alkaptonuria.
Ranganath LR; Milan AM; Hughes AT; Khedr M; Davison AS; Shweihdi E; Norman BP; Hughes JH; Bygott H; Luangrath E; Fitzgerald R; Psarelli EE; van Kan C; Laan D; Olsson B; Rudebeck M; Mankowitz L; Sireau N; Arnoux JB; Le Quan Sang KH; Jarvis JC; Genovese F; Braconi D; Santucci A; Zatkova A; Glasova H; Stančík R; Imrich R; Rhodes NP; Gallagher JA
J Inherit Metab Dis; 2020 Jul; 43(4):737-747. PubMed ID: 31609457
[TBL] [Abstract][Full Text] [Related]
2. Oxidative stress and mechanisms of ochronosis in alkaptonuria.
Braconi D; Millucci L; Bernardini G; Santucci A
Free Radic Biol Med; 2015 Nov; 88(Pt A):70-80. PubMed ID: 25733348
[TBL] [Abstract][Full Text] [Related]
3. Nitisinone arrests ochronosis and decreases rate of progression of Alkaptonuria: Evaluation of the effect of nitisinone in the United Kingdom National Alkaptonuria Centre.
Ranganath LR; Khedr M; Milan AM; Davison AS; Hughes AT; Usher JL; Taylor S; Loftus N; Daroszewska A; West E; Jones A; Briggs M; Fisher M; McCormick M; Judd S; Vinjamuri S; Griffin R; Psarelli EE; Cox TF; Sireau N; Dillon JP; Devine JM; Hughes G; Harrold J; Barton GJ; Jarvis JC; Gallagher JA
Mol Genet Metab; 2018 Sep; 125(1-2):127-134. PubMed ID: 30055994
[TBL] [Abstract][Full Text] [Related]
4. Exacerbation of the ochronosis of alkaptonuria due to renal insufficiency and improvement after renal transplantation.
Introne WJ; Phornphutkul C; Bernardini I; McLaughlin K; Fitzpatrick D; Gahl WA
Mol Genet Metab; 2002; 77(1-2):136-42. PubMed ID: 12359141
[TBL] [Abstract][Full Text] [Related]
5. Ochronotic pigmentation is caused by homogentisic acid and is the key event in alkaptonuria leading to the destructive consequences of the disease-A review.
Ranganath LR; Norman BP; Gallagher JA
J Inherit Metab Dis; 2019 Sep; 42(5):776-792. PubMed ID: 31282009
[TBL] [Abstract][Full Text] [Related]
6. Homogentisic acid induces autophagy alterations leading to chondroptosis in human chondrocytes: Implications in Alkaptonuria.
Galderisi S; Milella MS; Rossi M; Cicaloni V; Rossi R; Giustarini D; Spiga O; Tinti L; Salvini L; Tinti C; Braconi D; Millucci L; Lupetti P; Prischi F; Bernardini G; Santucci A
Arch Biochem Biophys; 2022 Mar; 717():109137. PubMed ID: 35090868
[TBL] [Abstract][Full Text] [Related]
7. Development of an in vitro model to investigate joint ochronosis in alkaptonuria.
Tinti L; Taylor AM; Santucci A; Wlodarski B; Wilson PJ; Jarvis JC; Fraser WD; Davidson JS; Ranganath LR; Gallagher JA
Rheumatology (Oxford); 2011 Feb; 50(2):271-7. PubMed ID: 20952450
[TBL] [Abstract][Full Text] [Related]
8. Homogentisic acid induces morphological and mechanical aberration of ochronotic cartilage in alkaptonuria.
Bernardini G; Leone G; Millucci L; Consumi M; Braconi D; Spiga O; Galderisi S; Marzocchi B; Viti C; Giorgetti G; Lupetti P; Magnani A; Santucci A
J Cell Physiol; 2019 May; 234(5):6696-6708. PubMed ID: 30341892
[TBL] [Abstract][Full Text] [Related]
9. Ochronotic osteoarthropathy in a mouse model of alkaptonuria, and its inhibition by nitisinone.
Preston AJ; Keenan CM; Sutherland H; Wilson PJ; Wlodarski B; Taylor AM; Williams DP; Ranganath LR; Gallagher JA; Jarvis JC
Ann Rheum Dis; 2014 Jan; 73(1):284-9. PubMed ID: 23511227
[TBL] [Abstract][Full Text] [Related]
10. Alkaptonuria: a very rare metabolic disorder.
Aquaron R
Indian J Biochem Biophys; 2013 Oct; 50(5):339-44. PubMed ID: 24772955
[TBL] [Abstract][Full Text] [Related]
11. Redox-proteomics of the effects of homogentisic acid in an in vitro human serum model of alkaptonuric ochronosis.
Braconi D; Bianchini C; Bernardini G; Laschi M; Millucci L; Spreafico A; Santucci A
J Inherit Metab Dis; 2011 Dec; 34(6):1163-76. PubMed ID: 21874298
[TBL] [Abstract][Full Text] [Related]
12. Nutritional interventions for patients with alkaptonuria: A minireview.
Imrich R; Zatkova A; Lukacova O; Sedlakova J; Zanova E; Vlcek M; Penesova A; Radikova Z; Havranova A; Ranganath L
Endocr Regul; 2023 Jan; 57(1):61-67. PubMed ID: 36966367
[TBL] [Abstract][Full Text] [Related]
13. A novel ex vivo organotypic culture model of alkaptonuria-ochronosis.
Tinti L; Spreafico A; Chellini F; Galeazzi M; Santucci A
Clin Exp Rheumatol; 2011; 29(4):693-6. PubMed ID: 21813063
[TBL] [Abstract][Full Text] [Related]
14. Dietary restriction of tyrosine and phenylalanine lowers tyrosinemia associated with nitisinone therapy of alkaptonuria.
Hughes JH; Wilson PJM; Sutherland H; Judd S; Hughes AT; Milan AM; Jarvis JC; Bou-Gharios G; Ranganath LR; Gallagher JA
J Inherit Metab Dis; 2020 Mar; 43(2):259-268. PubMed ID: 31503358
[TBL] [Abstract][Full Text] [Related]
15. Reduced primary cilia length and altered Arl13b expression are associated with deregulated chondrocyte Hedgehog signaling in alkaptonuria.
Thorpe SD; Gambassi S; Thompson CL; Chandrakumar C; Santucci A; Knight MM
J Cell Physiol; 2017 Sep; 232(9):2407-2417. PubMed ID: 28158906
[TBL] [Abstract][Full Text] [Related]
16. Conditional targeting in mice reveals that hepatic homogentisate 1,2-dioxygenase activity is essential in reducing circulating homogentisic acid and for effective therapy in the genetic disease alkaptonuria.
Hughes JH; Liu K; Plagge A; Wilson PJM; Sutherland H; Norman BP; Hughes AT; Keenan CM; Milan AM; Sakai T; Ranganath LR; Gallagher JA; Bou-Gharios G
Hum Mol Genet; 2019 Dec; 28(23):3928-3939. PubMed ID: 31600782
[TBL] [Abstract][Full Text] [Related]
17. Alkaptonuria is a novel human secondary amyloidogenic disease.
Millucci L; Spreafico A; Tinti L; Braconi D; Ghezzi L; Paccagnini E; Bernardini G; Amato L; Laschi M; Selvi E; Galeazzi M; Mannoni A; Benucci M; Lupetti P; Chellini F; Orlandini M; Santucci A
Biochim Biophys Acta; 2012 Nov; 1822(11):1682-91. PubMed ID: 22850426
[TBL] [Abstract][Full Text] [Related]
18. Alkaptonuria: From Molecular Insights to a Dedicated Digital Platform.
Milella MS; Geminiani M; Trezza A; Visibelli A; Braconi D; Santucci A
Cells; 2024 Jun; 13(12):. PubMed ID: 38920699
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of antioxidant drugs for the treatment of ochronotic alkaptonuria in an in vitro human cell model.
Tinti L; Spreafico A; Braconi D; Millucci L; Bernardini G; Chellini F; Cavallo G; Selvi E; Galeazzi M; Marcolongo R; Gallagher JA; Santucci A
J Cell Physiol; 2010 Oct; 225(1):84-91. PubMed ID: 20648626
[TBL] [Abstract][Full Text] [Related]
20. Suitability Of Nitisinone In Alkaptonuria 1 (SONIA 1): an international, multicentre, randomised, open-label, no-treatment controlled, parallel-group, dose-response study to investigate the effect of once daily nitisinone on 24-h urinary homogentisic acid excretion in patients with alkaptonuria after 4 weeks of treatment.
Ranganath LR; Milan AM; Hughes AT; Dutton JJ; Fitzgerald R; Briggs MC; Bygott H; Psarelli EE; Cox TF; Gallagher JA; Jarvis JC; van Kan C; Hall AK; Laan D; Olsson B; Szamosi J; Rudebeck M; Kullenberg T; Cronlund A; Svensson L; Junestrand C; Ayoob H; Timmis OG; Sireau N; Le Quan Sang KH; Genovese F; Braconi D; Santucci A; Nemethova M; Zatkova A; McCaffrey J; Christensen P; Ross G; Imrich R; Rovensky J
Ann Rheum Dis; 2016 Feb; 75(2):362-7. PubMed ID: 25475116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
